ISRCTN27093749已完成不适用
Rituximab in Rheumatoid Arthritis in patients who failed therapy with tumour necrosis factor-blockers: a multi-centre clinical observational real-life study (phase IIIb)
Medical University of Vienna (Austria)0 个研究点目标入组 20 人开始时间: 2006年12月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Women or men 18 years of age or older
- •2. Diagnosis of RA according to the revised 1987 criteria of the American Rheumtololgy Association (ARA) for at least three months prior to first administration of study medication
- •3. The current treatment with Etanercept, Infliximab or Adalimumab in combination with MTX is insufficient. The patient?s disease is considered to be active despite Disease Modifying Anti-Rheumatic Drug (DMARD) treatment
- •4. Active disease at the time of screening as defined by:
- •a. more than or equal to six swollen joints on a 66/68 joint count
- •b. more than or equal to six tender joints on a 66/68 joint count
- •c. and one out of the following three categories:
- •i. Erythrocyte Sedimentation Rate (ESR) more than or equal to 28 mm/h
- •ii. C-Reactive Protein (CRP) more than or equal to 1.5 mg/dl
- •iii. Morning stiffness more than or equal to 45 minutes
- •d. and one out of the following three categories:
- •i. bone erosion by x-ray prior to first administration of study medication
- •ii. Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibody-positive
- •iii. Rheumatoid Factor (RF)-positive at screening
- •5. If using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or other analgesics for RA, must be on a stable dose for at least two weeks prior to the first administration of study agent
- •6. If using oral corticosteroids, must be on a stable dose equivalent to less than or equal to 10 mg of prednisone/day for at least two weeks prior to first administration of study agent. If currently not using corticosteroids, the subject must not have received oral corticosteroids for at least two weeks prior to first administration of study medication
- •7. Women of childbearing potential or men capable of fathering children must be using adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilisation) during the study and for six months after receiving the last administration of study agent
- •8. Female subjects of childbearing potential must test negative for pregnancy. A pregnancy test will be performed at the beginning and at the end of the study
- •9. The screening laboratory test must meet the following criteria:
- •a. haemoglobin more than or equal to 8.5 g/dl providing the low haemoglobin level is not due to other diseases than anemia of chronic inflammation
- •b. White Blood Cells (WBC) more than or equal to 3500/µl
- •c. neutrophils more than or equal to 1500/µl
- •d. platelets more than or equal to 100,000/µl
- •e. serum transaminase less than or equal to two times the Upper Limit of Normal (ULN)
- •f. serum creatinine less than or equal to 1.7 mg/dl
- •10. The patient must be able to adhere the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures
排除标准
- •Patients are excluded if they meet one of the following criteria:
- •1. Pregnant women, nursing mothers or a planned pregnancy within six months after last scheduled treatment
- •2. Patients with other inflammatory diseases that might interfere with the evaluation of the RA
- •3. Patients with fibromyalgia syndrome
- •4. Use of IntraMuscular (IM), IntraVenous (IV), IntraArterial (IA) corticosteroids within four weeks prior to screening
- •5. Treatment with any investigational drug within three months prior to screening
- •6. A history of known allergy to murine proteins, e.g. allergy to Infliximab
- •7. History of infected joint prothesis within the previous five years
- •8. Chronic infections
- •9. History of active tuberculosis requiring treatment within the previous three years, or history of opportunistic infections within two months, uncontrolled active infection or documented Human Immunodeficiency Virus (HIV) infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis (TB) without documented adequate therapy if they will not be treated according to the local TB guidelines
- •10. Current signs or symptoms of other severe uncontrolled disease which in the investigators opinion would put the patient at an unacceptable risk
- •11. History of lymphoproliferative disease, any current malignancies or history of malignancy within five years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin
- •12. History of drug abuse
研究者
相似试验
进行中（未招募）
不适用
Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-BlockersRheumatoid ArthritisEUCTR2006-000854-32-ATVienna Medical University20
进行中（未招募）
不适用
Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070) - Efficacy of re-therapy in anti-TNFalpha IRMedDRA version: 9.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-006746-33-DERoche Pharma AG240
进行中（未招募）
不适用
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
招募中
2 期
Safety and Efficacy of Rituximab in patients with juvenile dermatomyositisJuvenile dermatomyositisJuvenile dermatomyositis.M33.0IRCT20231119060108N1Shahid Beheshti University of Medical Sciences7
进行中（未招募）
不适用
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300